Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
Head And Neck Squamous Cell Carcinoma
Explore 249 assets in Head And Neck Squamous Cell Carcinoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Asher Biotherapeutics, Inc.
Modality
other_biological
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05653882CT.gov A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa (this asset) | Asher Biotherapeutics, Inc. | P1 | CC · 41 |
| Carboplatin | Akeso | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Akeso | P3 | BB |
| Irinotecan | Neonc Technologies, Inc. | P2 | BB |
| Tisotumab Vedotin | Seagen, a wholly owned subsidiary of Pfizer | P2 | BB |
| Capecitabine | Merck Sharp & Dohme LLC | P2 | BB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Fluorouracilum | Akeso | P2 | BB |
+42 more in the Head And Neck Squamous Cell Carcinoma cohort
Other indications for Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 37 |
| Melanoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa in Head And Neck Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/humanized-immunoglobulin-g1-kappa-anti-human-cd8-fused-at-the-c-terminus-of-one-heavy-chain-via-peptide-linker-sup449sup-sggggsggggsggggssup464sup-to-a-variant-of-human-interleukin-2-glycoform-alfa-head-and-neck-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →